A new drug reduces airway hyperreactivity in asthma patients
Protein display drug ANDI reduces asthmatic airway hyperreactivity
This study is testing a new drug called ANDI that helps people with severe allergic asthma by targeting and removing certain antibodies that cause inflammation, with the goal of making it easier for them to breathe and reducing asthma attacks.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aaiit LLC NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11175827 on NIH RePORTER |
What this research studies
This research investigates a novel drug called ANDI, which targets and removes IgE antibodies bound to mast cells, a key factor in severe allergic asthma. By dissociating these antibodies, the drug aims to reduce inflammation and improve lung function in asthmatic patients. The study will involve assessing the drug's effectiveness in reducing asthma exacerbations and improving overall respiratory health. Patients may be monitored for changes in their symptoms and lung function during the treatment period.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from severe allergic asthma who have not achieved adequate control with existing treatments.
Not a fit: Patients with non-allergic asthma or those who do not have elevated IgE levels may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for asthma, potentially reducing symptoms and improving quality of life for patients.
How similar studies have performed: Previous research has shown promise with similar approaches targeting IgE in asthma treatment, but this specific drug is a novel development.
Where this research is happening
San Diego, United States
- Aaiit LLC — San Diego, United States (Active)
Researchers
- Principal investigator: Chen, Swey-Shen — Aaiit LLC
- Study coordinator: Chen, Swey-Shen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.